Publicaciones en colaboración con investigadores/as de Hospital Universitario Pío del Río Hortega (11)

2023

  1. Efficacy and safety of PARP inhibitor in non-small cell lung cancer: a systematic review with meta-analysis

    Chinese Clinical Oncology, Vol. 12, Núm. 6

2022

  1. Immunohistochemical Assessment of the P53 Protein as a Predictor of Non-Small Cell Lung Cancer Response to Immunotherapy

    Frontiers in bioscience (Landmark edition), Vol. 27, Núm. 3, pp. 88

  2. Influence of DNA Mismatch Repair (MMR) System in Survival and Response to Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC): Retrospective Analysis

    Biomedicines, Vol. 10, Núm. 2

2021

  1. Dopamine receptors and the kidney: An overview of health-and pharmacological-targeted implications

    Biomolecules, Vol. 11, Núm. 2, pp. 1-16

  2. Immune System Disorders, Cancer and Viral Infections: A New Treatment Opportunity for the Immune Checkpoint Inhibitors

    Life, Vol. 11, Núm. 12

  3. Resistance to immune checkpoint inhibitors secondary to myeloid-derived suppressor cells: A new therapeutic targeting of haematological malignancies

    Journal of Clinical Medicine, Vol. 10, Núm. 9

  4. The influence of diet and probiotics on the response of solid tumours to immunotherapy: Present and future perspectives

    Applied Sciences (Switzerland), Vol. 11, Núm. 18

2014

  1. Polimorfismos genéticos y riesgo de cáncer de pulmón: Un estudio de casos y controles

    Medicina Clinica, Vol. 143, Núm. 3, pp. 97-103

2005

  1. Weekly irinotecan plus UFT and leucovorin as first-line chemotherapy of patients with advanced colorectal cancer

    Investigational New Drugs, Vol. 23, Núm. 3, pp. 243-251

2003

  1. A multicenter phase II study of irinotecan in patients with advanced colorectal cancer previously treated with 5-fluorouracil

    Clinical Colorectal Cancer, Vol. 3, Núm. 3, pp. 174-179

  2. Biweekly docetaxel and vinorelbine in anthracycline-resistant metastatic breast cancer: A multicenter phase II study

    American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 26, Núm. 2, pp. 127-131